[1]
|
邹佳运, 杨天瑶, 王颖. RAS突变型转移性结直肠癌的精准治疗[J]. 肿瘤防治研究, 2021, 48(8): 820-824.
|
[2]
|
Cao, M., Li, H., Sun, D., et al. (2022) Current Cancer Burden in China: Epidemiology, Etiology, and Prevention. Cancer Biology & Medicine, 19, 1121-1138. https://doi.org/10.20892/j.issn.2095-3941.2022.0231
|
[3]
|
Yin, H., Fan, X., Zhang, Y., et al. (2022) An Integrated Study on the Differential Expression of the FOX Gene Family in Cancer and Their Response to Chemotherapy Drugs. Genes, 13, Article No. 1754.
https://doi.org/10.3390/genes13101754
|
[4]
|
Myatt, S.S. and Lam, E.W.-F. (2007) The Emerging Roles of Fork-head Box (Fox) Proteins in Cancer. Nature Reviews Cancer, 7, 847-859. https://doi.org/10.1038/nrc2223
|
[5]
|
Yang, W., Chen, H., Ma, L., et al. (2022) A Comprehensive Analysis of the FOX Family for Predicting Kidney Renal Clear Cell Carcinoma Prognosis and the Oncogenic Role of FOXG1. Aging, 14, 10107-10124.
https://doi.org/10.18632/aging.204448
|
[6]
|
Liu, Y., Ao, X., Jia, Y., et al. (2022) The FOXO Family of Transcrip-tion Factors: Key Molecular Players in Gastric Cancer. Journal of Molecular Medicine, 100, 997-1015. https://doi.org/10.1007/s00109-022-02219-x
|
[7]
|
Mani, S.A., Yang, J., Brooks, M., et al. (2007) Mesenchyme Forkhead 1 (FOXC2) Plays a Key Role in Metastasis and Is Associated with Aggressive Basal-Like Breast Cancers. Proceedings of the National Academy of Sciences of the United States of America, 104, 10069-10074. https://doi.org/10.1073/pnas.0703900104
|
[8]
|
Shimoda, Y., Ubukata, Y., Handa, T., et al. (2018) High Expression of Forkhead Box Protein C2 Is Associated with Aggressive Phenotypes and Poor Prognosis in Clinical Hepatocellular Carcinoma. BMC Cancer, 18, Article No. 597.
https://doi.org/10.1186/s12885-018-4503-6
|
[9]
|
Liu, C., Barger, C.J. and Karpf, A.R. (2021) FOXM1: A Multi-functional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer. Cancers, 13, Article No. 3065. https://doi.org/10.3390/cancers13123065
|
[10]
|
Iwafuchi, M., Cuesta, I., Donahue, G., et al. (2020) Gene Network Transitions in Embryos Depend Upon Interactions between a Pioneer Transcription Factor and Core Histones. Nature Genetics, 52, 418-427.
https://doi.org/10.1038/s41588-020-0591-8
|
[11]
|
Katoh, M. and Katoh, M. (2004) Identification and Characteriza-tion of Human FOXK1 Gene in Silico. International Journal of Molecular Medicine, 14, 127-132. https://doi.org/10.3892/ijmm.14.1.127
|
[12]
|
Bassel-Duby, R., Hernandez, M.D., Yang, Q., et al. (1994) Myocyte Nuclear Factor, a Novel Winged-Helix Transcription Factor under both Developmental and Neural Regulation in Striated Myocytes. Molecular and Cellular Biology, 14, 4596-605. https://doi.org/10.1128/mcb.14.7.4596-4605.1994
|
[13]
|
Bowman, C.J., Ayer, D.E. andDynlacht, B.D. (2014) Foxk Proteins Repress the Initiation of Starvation-Induced Atrophy and Autophagy Programs. Nature Cell Biology, 16, 1202-1214. https://doi.org/10.1038/ncb3062
|
[14]
|
Zhang, H., Wu, X., Xiao, Y., et al. (2019) Coexpression of FOXK1 and Vimentin Promotes EMT, Migration, and Invasion in Gastric Cancer Cells. Journal of Molecular Medicine, 97, 163-176.
https://doi.org/10.1007/s00109-018-1720-z
|
[15]
|
Peng, Y., Zhang, P., Huang, X., et al. (2016) Direct Regulation of FOXK1 by C-Jun Promotes Proliferation, Invasion and Metastasis in Gastric Cancer Cells. Cell Death & Disease, 7, e2480. https://doi.org/10.1038/cddis.2016.225
|
[16]
|
Zhang, P., Tang, W.M., Zhang, H., et al. (2017) MiR-646 In-hibited Cell Proliferation and EMT-Induced Metastasis by Targeting FOXK1 in Gastric Cancer. British Journal of Can-cer, 117, 525-534. https://doi.org/10.1038/bjc.2017.181
|
[17]
|
Wang, Y., Liu, G., Sun, S. and Qin, J. (2020) miR-1294 Alleviates Epithelial-Mesenchymal Transition by Repressing FOXK1 in Gastric Cancer. Genes Genomics, 42, 217-224. https://doi.org/10.1007/s13258-019-00899-3
|
[18]
|
Wang, Y., Qiu, W., Liu, N., et al. (2020) Forkhead Box K1 Regulates the Malignant Behavior of Gastric Cancer by Inhibiting Autophagy. Annals of Translational Medicine, 8, Article No. 107. https://doi.org/10.21037/atm.2019.12.123
|
[19]
|
Ganapathy-Kanniappan, S. and Geschwind, J.-F. (2013) Tumor Glycolysis as a Target for Cancer Therapy: Progress and Prospects. Molecular Cancer, 12, Article No. 152. https://doi.org/10.1186/1476-4598-12-152
|
[20]
|
Cui, H., Gao, Q., Zhang, L., Han, F. and Wang, L. (2018) Knockdown of FOXK1 Suppresses Liver Cancer Cell Viability by Inhibiting Glycolysis. Life Sciences, 213, 66-73. https://doi.org/10.1016/j.lfs.2018.10.018
|
[21]
|
Chen, W., Li, Y., Zhong, J. and Wen, G. (2021) Circ-PRKCI Targets miR-1294 and miR-186-5p by Downregulating FOXK1 Expression to Suppress Glycolysis in Hepatocellular Carcinoma. Molecular Medicine Reports, 23, Article No. 464. https://doi.org/10.3892/mmr.2021.12103
|
[22]
|
Xing, B., Shen, C., Yang, Q., Wang, Z. and Tan, W. (2023) miR-144-3p Represses Hepatocellular Carcinoma Progression by Affecting Cell Aerobic Glycolysis via FOXK1. International Journal of Experimental Pathology, 104, 117-127.
https://doi.org/10.1111/iep.12468
|
[23]
|
Cao, H., Chu, X., Wang, Z., et al. (2019) High FOXK1 Expression Corre-lates with Poor Outcomes in Hepatocellular Carcinoma and Regulates Stemness of Hepatocellular Carcinoma Cells. Life Sciences, 228, 128-134.
https://doi.org/10.1016/j.lfs.2019.04.068
|
[24]
|
Chen, F., Xiong, W., Dou, K. and Ran, Q. (2017) Knockdown of FOXK1 Suppresses Proliferation, Migration, and Invasion in Prostate Cancer Cells. Oncology Research, 25, 1261-1267.
https://doi.org/10.3727/096504017X14871164924588
|
[25]
|
Gu, Y., Jiang, J. and Liang, C. (2021) TFAP4 Pro-motes the Growth of Prostate Cancer Cells by Upregulating FOXK1. Experimental and Therapeutic Medicine, 22, Arti-cle No. 1299. https://doi.org/10.3892/etm.2021.10734
|
[26]
|
Shi, T., Li, R., Duan, P., et al. (2022) TRPM2-AS Promotes Paclitaxel Resistance in Prostate Cancer by Regulating FOXK1 via Sponging miR-497-5p. Drug Development Research, 83, 967-978. https://doi.org/10.1002/ddr.21924
|
[27]
|
Wu, Y., Xie, R., Liu, X., et al. (2016) Knockdown of FOXK1 Alone or in Combination with Apoptosis-Inducing 5-FU Inhibits Cell Growth in Colorectal Cancer. Oncolo-gy Reports, 36, 2151-2159. https://doi.org/10.3892/or.2016.5041
|
[28]
|
Xie, R., Wang, J., Liu, X., et al. (2017) RUFY3 Interaction with FOXK1 Promotes Invasion and Metastasis in Colorectal Cancer. Scientific Reports, 7, Article No. 3709. https://doi.org/10.1038/s41598-017-04011-1
|
[29]
|
Wang, J., Liu, G., Liu, M., et al. (2018) The FOXK1-CCDC43 Axis Promotes the Invasion and Metastasis of Colorectal Cancer Cells. Cellular Physiology and Bio-chemistry, 51, 2547-2563. https://doi.org/10.1159/000495924
|
[30]
|
Wu, W., Chen, Y., Ye, S., et al. (2021) Tran-scription Factor Forkhead Box K1 Regulates miR-32 Expression and Enhances Cell Proliferation in Colorectal Cancer. Oncology Letters, 21, Article No. 407.
https://doi.org/10.3892/ol.2021.12668
|
[31]
|
Huang, X., Xu, X., Ke, H., et al. (2022) MicroRNA-16-5p Suppresses Cell Proliferation and Angiogenesis in Colorectal Cancer by Negatively Regulating Forkhead Box K1 to Block the PI3K/Akt/mTOR Pathway. European Journal of Histochemistry, 66, Article No. 3333. https://doi.org/10.4081/ejh.2022.3333
|
[32]
|
Ma, W.C., Wang, J.H., Yu, Y., et al. (2020) FOXK1 Promotes Prolif-eration and Metastasis of Gallbladder Cancer by Activating AKT/mTOR Signaling Pathway. Frontiers in Oncology, 10, Article 545.
https://doi.org/10.3389/fonc.2020.00545
|
[33]
|
Gao, F. and Tian, J. (2020) FOXK1, Regulated by miR-365-3p, Promotes Cell Growth and EMT Indicates Unfavorable Prognosis in Breast Cancer. OncoTargets and Therapy, 13, 623-634. https://doi.org/10.2147/OTT.S212702
|
[34]
|
Xu, H., Liu, Y., Liu, Z., Wang, X. and Lu, X. (2021) Fork-head Box K1 Facilitates Growth of Papillary Thyroid Carcinoma Cells by Regulating Connective Tissue Growth Factor Expression. Human Cell, 34, 457-467.
https://doi.org/10.1007/s13577-020-00450-7
|
[35]
|
Li, L., Gong, M., Zhao, Y., Zhao, X. and Li, Q. (2017) FOXK1 Facilitates Cell Proliferation through Regulating the Expression of p21, and Promotes Metastasis in Ovarian Cancer. On-cotarget, 8, 70441-70451.
https://doi.org/10.18632/oncotarget.19713
|